Rheumatoid Arthritis Patients and Porphyromonas Gingivalis

Overview

Rheumatoid arthritis (RA) is the most frequent joint inflammatory disease inducing joint destruction strongly correlated with anti-citrullinated protein antibodies citrullinated anti-peptide (ACPA). Precise RA etiology remained unclear with a described association between RA and periodontal disease. The missing link could be a gram-negative anaerobic bacterium called Porphyromonas gingivalis (P. gingivalis), which is heavily involved in periodontal disease and able to induce gingival citrullinated protein via an enzyme called peptidyl arginine deiminase (PAD). DNA of P. gingivalis was detected in synovial tissue and in peripheral blood mononuclear cell. To improve knowledge of P. gingivalis involvement in RA, the investigators will compare its effect on various cell type with comparison with another oral bacteria Provatella intermedia.

Full Title of Study: “Porphyromonas Gingivalis Contribution in Rheumatoid Arthritis (RA).”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 27, 2016

Interventions

  • Procedure: blood sample
  • Procedure: synovial tissue
    • synoviocytes from synovial tissue

Arms, Groups and Cohorts

  • Rheumatoid arthritis
    • blood sample specimen and synoviocytes from synovial tissue
  • Osteoarthritis
    • blood sample specimen and synoviocytes from synovial tissue

Clinical Trial Outcome Measures

Primary Measures

  • Comparison of genetic signature after induction by P. gingivalis and P. intermedia on synoviocytes
    • Time Frame: day 1

Secondary Measures

  • Comparison of specific transcriptome profile induced by P. gingivalis compared to P. intermedia on peripheral blood mononuclear cells (PBMC) and gingival fibroblasts
    • Time Frame: day 1
  • Comparison of transcriptome profile between P. gingivalis and P. intermedia on RA synovial cells.
    • Time Frame: day 1
  • Comparison of the transcriptomic profile between RA and osteoarthritis synoviocytes
    • Time Frame: day 1

Participating in This Clinical Trial

Inclusion Criteria

  • Age >18 ans – RA or osteoarthritis with joint surgery planned – Informed consent approved and signed Exclusion Criteria:

  • Pregnancy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire de Saint Etienne
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Hubert Marotte, phD, Principal Investigator, CHU Saint-Etienne

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.